These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 38987565)
1. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Zhong Y; Liu J Cell Death Discov; 2024 Jul; 10(1):318. PubMed ID: 38987565 [TBL] [Abstract][Full Text] [Related]
2. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies. Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341 [TBL] [Abstract][Full Text] [Related]
3. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707 [TBL] [Abstract][Full Text] [Related]
4. The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer. Han J; Zhang B; Zheng S; Jiang Y; Zhang X; Mao K Cell Transplant; 2024; 33():9636897241231892. PubMed ID: 38433349 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Rafei H; Daher M; Rezvani K Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984 [TBL] [Abstract][Full Text] [Related]
6. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234 [TBL] [Abstract][Full Text] [Related]
7. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment. Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591 [TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy. Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827 [TBL] [Abstract][Full Text] [Related]
9. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026 [TBL] [Abstract][Full Text] [Related]
10. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905 [TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ Front Immunol; 2024; 15():1384039. PubMed ID: 38726000 [TBL] [Abstract][Full Text] [Related]
12. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future? Liu F; Miao X; Han L; Song X Front Oncol; 2024; 14():1390006. PubMed ID: 38863635 [TBL] [Abstract][Full Text] [Related]
13. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336 [TBL] [Abstract][Full Text] [Related]
14. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors. Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710 [TBL] [Abstract][Full Text] [Related]
15. Next Generation Natural Killer Cells for Cancer Immunotherapy. Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY Front Immunol; 2022; 13():886429. PubMed ID: 35720306 [TBL] [Abstract][Full Text] [Related]
16. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294 [TBL] [Abstract][Full Text] [Related]
17. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M Front Immunol; 2024; 15():1361194. PubMed ID: 38404574 [TBL] [Abstract][Full Text] [Related]
18. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Lu H; Zhao X; Li Z; Hu Y; Wang H Front Oncol; 2021; 11():720501. PubMed ID: 34422667 [TBL] [Abstract][Full Text] [Related]
19. CAR-NK Cells: From Natural Basis to Design for Kill. Khawar MB; Sun H Front Immunol; 2021; 12():707542. PubMed ID: 34970253 [TBL] [Abstract][Full Text] [Related]